Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00415350
Status:
COMPLETED
Last Update Posted:
2020-05-28
First Post:
2006-12-21
Brief Title:
Bronchiectasis and Long Term Azithromycin Treatment
Sponsor:
WGBoersma
Organization:
Medical Center Alkmaar
Study Overview
Official Title:
Bronchiectasis and Long Term Azithromycin Treatment A Randomised Placebo-controlled Trial Studying Disease Modifying Effects of Immunomodulating Treatment
Status:
COMPLETED
Status Verified Date:
2020-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BAT
Brief Summary:
1 SUMMARY
Rationale Patients with bronchiectasis often experience lower respiratory tract infections with progression of symptoms and decline in quality of life Macrolides as has been shown in panbronchiolitis and cystic fibrosis may break or weaken the link between infection and inflammation resulting in an improvement of symptoms Also the number of exacerbations may lowered
Objective A reduction in number of infective exacerbations and improvement in lung function by AZT treatment are the primary objectives Secondary objectives that will be evaluated are symptoms score quality of life inflammatory parameters bacterial colonisation and adverse events
Study design Randomised double blind multicenter study in the Netherlands Patients will be stratified for colonisation with Paeruginosa
Study population Patients with bronchiectasis demonstrated by high-resolution computed tomography HR-CT scan or bronchography
Intervention Patients receive Azithromycin 250mgpo once daily or placebo
Main study parametersendpoints Reduction in number exacerbations defined as increase symptoms such as dyspnoea coughing and sputum production for which a course of prednisolone andor antibiotic is needed Change in lung function parameters forced expiratory volume in 1 second FEV1 forced vital capacity FVC measured by spirometry is the other primary endpoint
Nature and extent of the burden and risks associated with participation benefit and group relatedness The risk of participating in this study is low Laboratory radiographic examinations and pulmonary function tests are commonly used as diagnostic procedures during outpatients visits and during exacerbations Adverse effects in maintenance treatment with AZT are usually mild and mainly gastrointestinal Sometimes rash and abnormal liver function tests are observed A better quality of life will probably be the beneficial effect of long term treatment with AZT This will be achieved by a reduction in respiratory and non-respiratory symptoms and number of exacerbations
Rationale Patients with bronchiectasis often experience lower respiratory tract infections with progression of symptoms and decline in quality of life Macrolides as has been shown in panbronchiolitis and cystic fibrosis may break or weaken the link between infection and inflammation resulting in an improvement of symptoms Also the number of exacerbations may lowered
Objective A reduction in number of infective exacerbations and improvement in lung function by AZT treatment are the primary objectives Secondary objectives that will be evaluated are symptoms score quality of life inflammatory parameters bacterial colonisation and adverse events
Study design Randomised double blind multicenter study in the Netherlands Patients will be stratified for colonisation with Paeruginosa
Study population Patients with bronchiectasis demonstrated by high-resolution computed tomography HR-CT scan or bronchography
Intervention Patients receive Azithromycin 250mgpo once daily or placebo
Main study parametersendpoints Reduction in number exacerbations defined as increase symptoms such as dyspnoea coughing and sputum production for which a course of prednisolone andor antibiotic is needed Change in lung function parameters forced expiratory volume in 1 second FEV1 forced vital capacity FVC measured by spirometry is the other primary endpoint
Nature and extent of the burden and risks associated with participation benefit and group relatedness The risk of participating in this study is low Laboratory radiographic examinations and pulmonary function tests are commonly used as diagnostic procedures during outpatients visits and during exacerbations Adverse effects in maintenance treatment with AZT are usually mild and mainly gastrointestinal Sometimes rash and abnormal liver function tests are observed A better quality of life will probably be the beneficial effect of long term treatment with AZT This will be achieved by a reduction in respiratory and non-respiratory symptoms and number of exacerbations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| BAT-2006 | None | None | None |